Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insulet Corporation PODD

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.


Recent & Breaking News (NDAQ:PODD)

Insulet to Present at Upcoming Investor Conferences

Business Wire November 22, 2022

Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller

Business Wire November 14, 2022

Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Business Wire November 4, 2022

Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)

Business Wire November 3, 2022

Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November

Business Wire November 1, 2022

Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022

Business Wire September 22, 2022

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Business Wire September 20, 2022

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Business Wire August 22, 2022

Insulet to Present at Upcoming Investor Conferences

Business Wire August 5, 2022

Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)

Business Wire August 4, 2022

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

Business Wire August 1, 2022

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

Business Wire June 30, 2022

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Business Wire June 3, 2022

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

Business Wire June 2, 2022

Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia

Business Wire June 1, 2022

AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

GlobeNewswire May 12, 2022

Insulet Announces CEO Transition

Business Wire May 5, 2022

Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year

Business Wire May 5, 2022

Insulet's 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose

Business Wire May 2, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Business Wire April 27, 2022